List of technologies with approved Patient Access Schemes, recommended by NICE for use in the NHS.
|
TA Ref |
Treatment |
Indication |
Company |
|
TA185 |
|
Advanced soft tissue sarcoma |
PharmaMar |
|
TA155 |
|
Macular degeneration (Acute wet AMD) |
Novartis |
|
TA171 |
|
Multiple myeloma |
Celgene |
|
TA162 |
|
Non small cell lung cancer |
Roche |
|
TA129 |
|
Multiple myeloma |
JC |
|
TA180 |
|
Moderate to severe psoriasis |
J&J / JC |
|
TA179 |
|
Gastrointestinal stromal tumour |
Pfizer |
|
TA176 |
|
Metastatic colorectal cancer (first Line) |
Merck S. |
|
TA169 |
|
Renal cell carcinoma |
Pfizer |
|
TA186 |
|
Rheumatoid arthritis |
UCB |
|
TA192 |
|
Non small cell lung cancer |
AstraZeneca |
|
TA215 |
|
Advanced renal cell carcinoma |
GSK |
|
TA218 |
|
Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia |
Celgene |
|
TA220 |
|
Psoriatic arthritis |
Merck Sharp & Dohme |
|
TA221 |
|
Chronic idiopathic (immune) thrombocytopenic purpura |
Amgen |
|
TA225 |
|
Rheumatoid arthritis |
Merck Sharp & Dohme |
|
TA233 |
|
Ankylosing spondylitis |
Merck Sharp & Dohme |
|
TA235
|
|
High grade resectable non-metastatic osteosarcoma
|
Takeda
|
|
TA238
|
|
Systemic juvenile idiopathic arthritis
|
Roche
|
|
TA241
|
|
Imatinib-resistant chronic myeloid leukaemia
|
Novartis
|
|
TA247 |
|
Rheumatoid arthritis |
Roche |
|
TA251 |
|
First-line treatment of chronic myeloid leukaemia |
Novartis |
This page was last updated: 24 May 2012
